Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Cash & Equivalents for 3 consecutive years, with $124.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 18.61% year-over-year to $124.2 million; the TTM figure through Dec 2025 stood at $124.2 million (down 18.61% YoY), while the FY2025 annual figure was $124.2 million, down 18.61% from the prior year.
• Cash & Equivalents slipped to $124.2 million in Q4 2025 per INBX's latest filing, from $153.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $277.9 million in Q4 2023 and bottomed at $124.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $191.8 million across 3 years, with a median of $191.4 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 45.09% — and 2025, when it slipped 17.76%.
• Inhibrx Biosciences' Cash & Equivalents stood at $277.9 million in 2023, then plunged by 45.09% to $152.6 million in 2024, then dropped by 18.61% to $124.2 million in 2025.
• Business Quant data shows INBX's Cash & Equivalents at $124.2 million in Q4 2025, $153.1 million in Q3 2025, and $186.6 million in Q2 2025.